Dali Pharmaceuticalco.,Ltd

Shanghai Stock Exchange 603963.SS

Dali Pharmaceuticalco.,Ltd Market Capitalization on January 14, 2025: USD 55.12 M

Dali Pharmaceuticalco.,Ltd Market Capitalization is USD 55.12 M on January 14, 2025, a -84.39% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Dali Pharmaceuticalco.,Ltd 52-week high Market Capitalization is USD 487.17 M on March 21, 2024, which is 783.78% above the current Market Capitalization.
Dali Pharmaceuticalco.,Ltd 52-week low Market Capitalization is USD 55.12 M on January 14, 2025, which is 0.00% below the current Market Capitalization.
Dali Pharmaceuticalco.,Ltd average Market Capitalization for the last 52 weeks is USD 150.79 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Shanghai Stock Exchange: 603963.SS

Dali Pharmaceuticalco.,Ltd

CEO	Mr. Jun Xiang Yang
IPO Date	Sept. 22, 2017
Location	China
Headquarters	No. 118, West Huancheng Road
Employees	272
Sector	Health Care
Industries Pharmaceuticals

Description

Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.

Key trends

Past 5 years